A Preview Of Lineage Cell Therapeutics's Earnings
Portfolio Pulse from Benzinga Insights
Lineage Cell Therapeutics (AMEX:LCTX) is scheduled to release its quarterly earnings report on March 7, 2024, with an expected EPS of $-0.04. The company's past earnings performance shows a consistent EPS estimate of $-0.04 over the last four quarters, with actual EPS slightly beating estimates in Q2 and Q1 2023 but matching the estimate in Q3 2023 and Q4 2022. The stock price reacted with minor fluctuations following these earnings releases. Currently, LCTX shares are trading at $1.08, reflecting a 22.6% decline over the last 52 weeks.

March 06, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Lineage Cell Therapeutics is expected to report an EPS of $-0.04 for the upcoming quarter. Historical data shows minor fluctuations in stock price following earnings announcements. Shares have declined 22.6% over the last year.
Given the historical performance and the consistent EPS estimates, the upcoming earnings report for LCTX may not significantly impact the stock price in the short term. The stock's recent downward trend and the minor fluctuations following past earnings releases suggest a neutral short-term impact. However, any unexpected positive guidance could provide a positive surprise.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100